Core Viewpoint - WuXi Biologics (02269) is a leading global provider of biologics services, experiencing a stock price increase of 2.17% to HKD 32.0 per share as of August 22, with a trading volume of HKD 305 million [1] Company Overview - WuXi Biologics offers comprehensive, integrated, and highly customized services covering the entire process from discovery and development to the production of biologics [1] - The company held a 48% market share in China's biologics R&D market in 2016 and has established partnerships with 12 out of the top 20 global pharmaceutical companies [1] Financial Performance - As of the mid-year report in 2025, WuXi Biologics reported total revenue of HKD 9.953 billion and a net profit of HKD 2.339 billion [1] Analyst Rating - On August 21, CMB International maintained a "Buy" rating for WuXi Biologics, raising the target price to HKD 35.6 [1]
药明生物(02269)上涨2.17%，报32.0元/股